CN103261176B - 1,4-氧杂氮杂环庚烷衍生物 - Google Patents
1,4-氧杂氮杂环庚烷衍生物 Download PDFInfo
- Publication number
- CN103261176B CN103261176B CN201180059036.1A CN201180059036A CN103261176B CN 103261176 B CN103261176 B CN 103261176B CN 201180059036 A CN201180059036 A CN 201180059036A CN 103261176 B CN103261176 B CN 103261176B
- Authority
- CN
- China
- Prior art keywords
- compound
- optionally substituted
- alkyl
- group
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C1OCCN(*)CC1c1ccccc1 Chemical compound *C1OCCN(*)CC1c1ccccc1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010227864 | 2010-10-07 | ||
| JP2010-227864 | 2010-10-07 | ||
| JP2011-175336 | 2011-08-10 | ||
| JP2011175336 | 2011-08-10 | ||
| PCT/JP2011/073745 WO2012046882A1 (en) | 2010-10-07 | 2011-10-05 | 1,4-oxazepane derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103261176A CN103261176A (zh) | 2013-08-21 |
| CN103261176B true CN103261176B (zh) | 2015-06-03 |
Family
ID=44906302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180059036.1A Expired - Fee Related CN103261176B (zh) | 2010-10-07 | 2011-10-05 | 1,4-氧杂氮杂环庚烷衍生物 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8722662B2 (https=) |
| EP (1) | EP2625170A1 (https=) |
| JP (1) | JP5873487B2 (https=) |
| KR (1) | KR20130116073A (https=) |
| CN (1) | CN103261176B (https=) |
| AR (1) | AR083313A1 (https=) |
| AU (1) | AU2011313150A1 (https=) |
| BR (1) | BR112013008420A2 (https=) |
| CA (1) | CA2813911A1 (https=) |
| CL (1) | CL2013000927A1 (https=) |
| CO (1) | CO6700872A2 (https=) |
| CR (1) | CR20130158A (https=) |
| DO (1) | DOP2013000074A (https=) |
| EA (1) | EA201390491A1 (https=) |
| EC (1) | ECSP13012593A (https=) |
| GE (1) | GEP20156295B (https=) |
| IL (1) | IL225189A0 (https=) |
| MX (1) | MX2013003749A (https=) |
| NZ (1) | NZ608499A (https=) |
| PE (1) | PE20140239A1 (https=) |
| PH (1) | PH12013500657A1 (https=) |
| SG (1) | SG188346A1 (https=) |
| TW (1) | TW201242956A (https=) |
| UY (1) | UY33650A (https=) |
| WO (1) | WO2012046882A1 (https=) |
| ZA (1) | ZA201302112B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2630677C2 (ru) * | 2011-12-21 | 2017-09-12 | Оно Фармасьютикал Ко., Лтд. | Соединения |
| CA2918814C (en) * | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| CN105693652B (zh) * | 2014-11-27 | 2019-01-08 | 常州合全药业有限公司 | 一种4-叔丁基-5-乙基-6-氧亚基-1,4-噁吖庚环-4,5-二甲酸基酯的合成方法 |
| MX385021B (es) | 2014-12-10 | 2025-03-14 | Ono Pharmaceutical Co | Derivado de dihidroindolizinona. |
| US10414723B2 (en) | 2015-05-08 | 2019-09-17 | Vertellus Holdings Llc | Processes for converting carboxamides to thiocarboxamides |
| WO2024251807A1 (en) * | 2023-06-08 | 2024-12-12 | Cybin Irl Limited | Companion animal treatments |
| IL325385A (en) * | 2023-06-27 | 2026-02-01 | Rycarma Therapeutics Inc | Agents for the treatment of ryanodine receptor-related disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4010166A (en) * | 1974-11-25 | 1977-03-01 | Ciba-Geigy Corporation | 1,4-Oxazepines |
| US4499087A (en) * | 1982-11-20 | 1985-02-12 | Basf Aktiengesellschaft | 7-Phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepines and their use |
| CN1711250A (zh) * | 2002-12-20 | 2005-12-21 | 阿拉凯斯有限公司 | 苯并噁吖辛因及其作为单胺再摄取抑制剂的用途 |
| WO2007104933A1 (en) * | 2006-03-10 | 2007-09-20 | Astrazeneca Ab | Chemical compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3018222A (en) | 1956-08-28 | 1962-01-23 | Ravensberg G M B H | Central stimulant and appetite depressant composition |
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| JP3238414B2 (ja) | 1996-02-22 | 2001-12-17 | ニューロサーチ・アクティーゼルスカブ | トロパン―誘導体、その製造方法及びその使用方法 |
| PT929574E (pt) | 1996-08-27 | 2005-11-30 | Praecis Pharm Inc | Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos |
| AU2001293372A1 (en) | 2000-04-18 | 2001-10-30 | Cytovia, Inc. | Substituted 1,4-thiazepine and analogs and their use as activators of caspases |
| TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| WO2007049041A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
| BRPI0712429A2 (pt) | 2006-05-31 | 2014-03-11 | Hoffmann La Roche | Derivados de benzazepina como inibidores de re-captação de monoamina |
| JP2010510962A (ja) | 2006-11-24 | 2010-04-08 | 武田薬品工業株式会社 | 複素単環化合物およびその用途 |
| GB0721178D0 (en) | 2007-10-29 | 2007-12-05 | Glaxo Group Ltd | Chemical compounds |
| WO2009119528A1 (ja) | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2010016554A1 (ja) | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | 環状アミン化合物 |
-
2011
- 2011-10-05 EP EP11778987.5A patent/EP2625170A1/en not_active Withdrawn
- 2011-10-05 JP JP2013515601A patent/JP5873487B2/ja not_active Expired - Fee Related
- 2011-10-05 TW TW100136019A patent/TW201242956A/zh unknown
- 2011-10-05 MX MX2013003749A patent/MX2013003749A/es active IP Right Grant
- 2011-10-05 UY UY0001033650A patent/UY33650A/es unknown
- 2011-10-05 US US13/253,293 patent/US8722662B2/en not_active Expired - Fee Related
- 2011-10-05 WO PCT/JP2011/073745 patent/WO2012046882A1/en not_active Ceased
- 2011-10-05 KR KR1020137011425A patent/KR20130116073A/ko not_active Withdrawn
- 2011-10-05 EA EA201390491A patent/EA201390491A1/ru unknown
- 2011-10-05 US US13/877,810 patent/US20130267494A1/en not_active Abandoned
- 2011-10-05 SG SG2013015268A patent/SG188346A1/en unknown
- 2011-10-05 PH PH1/2013/500657A patent/PH12013500657A1/en unknown
- 2011-10-05 AR ARP110103695A patent/AR083313A1/es unknown
- 2011-10-05 GE GEAP201113078A patent/GEP20156295B/en unknown
- 2011-10-05 CN CN201180059036.1A patent/CN103261176B/zh not_active Expired - Fee Related
- 2011-10-05 PE PE2013000801A patent/PE20140239A1/es not_active Application Discontinuation
- 2011-10-05 CA CA2813911A patent/CA2813911A1/en not_active Abandoned
- 2011-10-05 NZ NZ60849911A patent/NZ608499A/en not_active IP Right Cessation
- 2011-10-05 BR BR112013008420A patent/BR112013008420A2/pt not_active IP Right Cessation
- 2011-10-05 AU AU2011313150A patent/AU2011313150A1/en not_active Abandoned
-
2013
- 2013-03-13 IL IL225189A patent/IL225189A0/en unknown
- 2013-03-20 ZA ZA2013/02112A patent/ZA201302112B/en unknown
- 2013-04-04 CR CR20130158A patent/CR20130158A/es not_active Application Discontinuation
- 2013-04-04 DO DO2013000074A patent/DOP2013000074A/es unknown
- 2013-04-05 CL CL2013000927A patent/CL2013000927A1/es unknown
- 2013-04-29 EC ECSP13012593 patent/ECSP13012593A/es unknown
- 2013-05-07 CO CO13114306A patent/CO6700872A2/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4010166A (en) * | 1974-11-25 | 1977-03-01 | Ciba-Geigy Corporation | 1,4-Oxazepines |
| US4499087A (en) * | 1982-11-20 | 1985-02-12 | Basf Aktiengesellschaft | 7-Phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepines and their use |
| CN1711250A (zh) * | 2002-12-20 | 2005-12-21 | 阿拉凯斯有限公司 | 苯并噁吖辛因及其作为单胺再摄取抑制剂的用途 |
| WO2007104933A1 (en) * | 2006-03-10 | 2007-09-20 | Astrazeneca Ab | Chemical compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CO6700872A2 (es) | 2013-06-28 |
| KR20130116073A (ko) | 2013-10-22 |
| MX2013003749A (es) | 2013-05-09 |
| PH12013500657A1 (en) | 2013-05-06 |
| BR112013008420A2 (pt) | 2016-06-28 |
| AR083313A1 (es) | 2013-02-13 |
| DOP2013000074A (es) | 2014-07-31 |
| GEP20156295B (en) | 2015-06-10 |
| ECSP13012593A (es) | 2013-07-31 |
| TW201242956A (en) | 2012-11-01 |
| WO2012046882A1 (en) | 2012-04-12 |
| JP5873487B2 (ja) | 2016-03-01 |
| EA201390491A1 (ru) | 2013-11-29 |
| UY33650A (es) | 2012-04-30 |
| IL225189A0 (en) | 2013-06-27 |
| PE20140239A1 (es) | 2014-03-07 |
| NZ608499A (en) | 2015-03-27 |
| US8722662B2 (en) | 2014-05-13 |
| CL2013000927A1 (es) | 2013-09-13 |
| SG188346A1 (en) | 2013-04-30 |
| CR20130158A (es) | 2013-05-03 |
| CA2813911A1 (en) | 2012-04-12 |
| EP2625170A1 (en) | 2013-08-14 |
| US20120088748A1 (en) | 2012-04-12 |
| JP2013538786A (ja) | 2013-10-17 |
| ZA201302112B (en) | 2013-12-23 |
| AU2011313150A1 (en) | 2013-04-18 |
| US20130267494A1 (en) | 2013-10-10 |
| CN103261176A (zh) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7968571B2 (en) | 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease | |
| CN104254533B (zh) | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 | |
| CN104169275B (zh) | 用作激酶抑制剂的三唑取代的吡啶化合物 | |
| CN103261176B (zh) | 1,4-氧杂氮杂环庚烷衍生物 | |
| JP7307734B2 (ja) | キナーゼ阻害剤としてのアミノピロロトリアジン | |
| US11713312B2 (en) | Substituted bicyclic compounds as farnesoid X receptor modulators | |
| JP2020530446A (ja) | 化合物、組成物、及び、方法 | |
| CN104159896A (zh) | 用作激酶抑制剂的杂环取代的吡啶基化合物 | |
| AU2012206527A1 (en) | BACE-2 inhibitors for the treatment of metabolic disorders | |
| JP2023533604A (ja) | ビシクロヘプタンピロリジンオレキシン受容体アゴニスト | |
| CN104755465A (zh) | 杂环化合物 | |
| MX2012005518A (es) | Derivados de pirazol amina triciclica. | |
| CN113302183A (zh) | 环脲 | |
| JP2000204084A (ja) | チオカルバミド酸誘導体 | |
| TW202115081A (zh) | 抗流感病毒化合物及其製備方法和用途 | |
| US8394837B2 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| EP2077719A2 (en) | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2020085234A1 (ja) | モルヒナン誘導体 | |
| TWI881587B (zh) | 類木瓜蛋白酶(PLpro)抑制劑 | |
| US20260069602A1 (en) | Compounds, compositions, and methods | |
| TW202220978A (zh) | 雜環化合物 | |
| HK1224663A1 (zh) | 取代的尿嘧啶及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150603 Termination date: 20171005 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |